| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
Department of Pharmacology, 3M Pharmaceuticals, St. Paul, MN 55144
Synthetic immune response modifiers (IRM) such as imidazoquinolines can selectively activate human TLR7 or TLR8. Although these endosomal TLRs are close relatives, TLR7-deficient mice are unresponsive to TLR8 agonist IRMs. Similarly, natural ssRNA cannot activate murine TLR8, leading to the belief that murine TLR8 is nonfunctional. In this study, we transfected HEK293 cells with murine TLR8 and NF-
B reporter constructs and stimulated them with combinations of IRM and oligodeoxynucleotides (ODNs). When stimulated with TLR7 or TLR8 agonists alone, no NF-B response was observed. However, a combination of polyT ODN plus the TLR8 agonist activated NF-B, whereas polyT ODN plus the TLR7 agonist did not activate. Primary mouse cells responded to the IRM/polyT ODN by secreting TNF. Cells from TLR7–/– and TLR9–/– mice responded to the IRM/polyT ODN combination, whereas MyD88–/– cells did not respond. In conclusion, this study demonstrates for the first time that mouse TLR8 is functional.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Address correspondence and reprint requests to Dr. Sefik S. Alkan, 3M Pharmaceuticals, 3M Center, 270-2S-06, St. Paul, MN 55144. E-mail address: ssalkan{at}mmm.com
2 Abbreviations used in this paper: IRM, immune response modifier; ODN, oligodeoxynucleotide.
This article has been cited by other articles:
|
|
 |
|
  A. M. Soulika, E. Lee, E. McCauley, L. Miers, P. Bannerman, and D. Pleasure Initiation and Progression of Axonopathy in Experimental Autoimmune Encephalomyelitis J. Neurosci., November 25, 2009; 29(47): 14965 - 14979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Baenziger, M. Heikenwalder, P. Johansen, E. Schlaepfer, U. Hofer, R. C. Miller, S. Diemand, K. Honda, T. M. Kundig, A. Aguzzi, et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology Blood, January 8, 2009; 113(2): 377 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Wang, G. N. Bowen, C. Padden, A. Cerny, R. W. Finberg, P. E. Newburger, and E. A. Kurt-Jones Toll-like receptor-mediated activation of neutrophils by influenza A virus Blood, September 1, 2008; 112(5): 2028 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Wynn, P. O. Scumpia, R. D. Winfield, M. J. Delano, K. Kelly-Scumpia, T. Barker, R. Ungaro, O. Levy, and L. L. Moldawer Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists Blood, September 1, 2008; 112(5): 1750 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy Oncologist, August 1, 2008; 13(8): 859 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-L. Santiago-Raber, S. Kikuchi, P. Borel, S. Uematsu, S. Akira, B. L. Kotzin, and S. Izui Evidence for Genes in Addition to Tlr7 in the Yaa Translocation Linked with Acceleration of Systemic Lupus Erythematosus J. Immunol., July 15, 2008; 181(2): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Butchi, S. Pourciau, M. Du, T. W. Morgan, and K. E. Peterson Analysis of the Neuroinflammatory Response to TLR7 Stimulation in the Brain: Comparison of Multiple TLR7 and/or TLR8 Agonists J. Immunol., June 1, 2008; 180(11): 7604 - 7612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Forsbach, J.-G. Nemorin, C. Montino, C. Muller, U. Samulowitz, A. P. Vicari, M. Jurk, G. K. Mutwiri, A. M. Krieg, G. B. Lipford, et al. Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses J. Immunol., March 15, 2008; 180(6): 3729 - 3738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dummer, A. Hauschild, J. C. Becker, J.-J. Grob, D. Schadendorf, V. Tebbs, J. Skalsky, K. C. Kaehler, S. Moosbauer, R. Clark, et al. An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma Clin. Cancer Res., February 1, 2008; 14(3): 856 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Camateros, M. Tamaoka, M. Hassan, R. Marino, J. Moisan, D. Marion, M.-C. Guiot, J. G. Martin, and D. Radzioch Chronic Asthma-induced Airway Remodeling Is Prevented by Toll-like Receptor-7/8 Ligand S28463 Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1241 - 1249. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
